Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Tempest Therapeutics, Inc. Common Stock

TPST

Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.

Last trade $0.323
Day change -$0.0188 (-5.50%)
Day range $0.306 – $0.37
Volume 161,409
Market cap $7M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$6.8M
Price / earnings
—
Price / book
-3.71×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.15×

Profitability

Earnings per share
-$1.99
Return on assets
-454.1%
Return on equity
2,173.99%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-0×
Current ratio
0.34×
Quick ratio
0.34×
Cash ratio
0.19×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TPST, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$2.62M$3.43M$5.43M$3.54M$3.03M$4.1M$3.31M$3.18M
Research and development$207K$1.82M$22.29M$539K$570K$3.87M$7.63M$10.74M
Total operating expenses$2.82M$5.25M$27.72M$4.08M$3.6M$7.97M$10.94M$13.92M
Operating income-$2.82M-$5.25M-$27.72M-$4.08M-$3.6M-$7.97M-$10.94M-$13.92M
Interest expense$0$0$0$0$0-$46K-$161K-$247K
Income before taxes-$2.82M-$5.24M-$27.7M-$4.02M-$3.6M-$7.87M-$10.86M-$13.81M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.82M-$5.24M-$27.7M-$4.02M-$3.6M-$7.87M-$10.86M-$13.81M
Net income attributable to common shareholders-$2.82M-$5.24M-$27.7M-$4.02M-$3.6M-$7.87M-$10.86M-$13.81M
EBITDA-$2.77M-$5.19M-$27.66M-$4.01M-$3.53M-$7.9M-$10.87M-$13.87M
Basic earnings per share-$0.21-$0.34-$2.53-$0.82-$0.79-$2.07-$3.16-$4.38
Diluted earnings per share-$0.21-$0.34-$2.53-$0.82-$0.79-$2.07-$3.16-$4.38

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update

Tempest Therapeutics (TPST) announced it has exercised an option to obtain exclusive global rights (excluding China) to Senlang's CD7-targeted lentiviral vector platform and in vivo CAR-T candidates. The company's lead candidate TPST-4903, a BCMA/GPRC5D dual-targeting in vivo CAR-T, is in Phase 1 trials for relapsed/refractory multiple myeloma with encouraging preliminary results expected to be presented at an upcoming conference. Tempest also secured $50 million in equity line of credit access and $2.5 million in private placement funding, while strengthening its board with two new independent directors.

GlobeNewswire Inc.

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

Tempest Therapeutics will present updated clinical data from its REDEEM-1 Phase 1/2a trial of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma, at the International Society for Cell & Gene Therapy Scientific Annual Meeting in Dublin (May 6-9, 2026). Earlier interim data showed a 100% complete response rate among six evaluable patients with a favorable safety profile.

GlobeNewswire Inc.

Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026

Tempest Therapeutics selected Cincinnati Children's Applied Gene and Cell Therapy Center as its manufacturing partner for technology transfer of TPST-2003, a dual-targeting CD19/BCMA CAR-T therapy for relapsed/refractory multiple myeloma. The partnership supports preparation for a planned U.S. registrational study with IND filing targeted for Q4 2026. Recent interim data from the REDEEM-1 trial showed 100% complete response rate in all six efficacy evaluable patients and 100% overall response rate among 25 evaluable patients with measurable disease.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 9, 20251-for-13reverse split